List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1901138/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology, 2011, 7, 330-339.	8.0	482
2	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood, 2003, 101, 3495-3500.	1.4	290
3	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. Seminars in Thrombosis and Hemostasis, 2008, 34, 236-250.	2.7	205
4	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Annals of the Rheumatic Diseases, 2007, 66, 1327-1333.	0.9	184
5	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. Aids, 1994, 8, 757-762.	2.2	159
6	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathologica Communications, 2016, 4, 47.	5.2	147
7	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis and Rheumatism, 2002, 46, 1602-1613.	6.7	137
8	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology, 2020, 11, 584241.	4.8	137
9	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 609-615.	0.9	132
10	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
11	A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	1.4	120
12	In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood, 2011, 118, 4231-4238.	1.4	113
13	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nature Reviews Rheumatology, 2018, 14, 433-440.	8.0	95
14	Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism. Arthritis and Rheumatology, 2015, 67, 1155-1164.	5.6	94
15	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β ₂ â€Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. Arthritis and Rheumatology, 2015, 67, 2196-2204.	5.6	94
16	Imbalance of Osteoclastogenesis-Regulating Factors in Patients With Celiac Disease. Journal of Bone and Mineral Research, 2004, 19, 1112-1121.	2.8	91
17	Endothelial cell activation by antiphospholipid antibodies. Clinical Immunology, 2004, 112, 169-174.	3.2	91
18	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 715-726.	8.0	85

#	Article	IF	CITATIONS
19	Patients with antiphospholipid syndrome display endothelial perturbation. Journal of Autoimmunity, 2010, 34, 105-110.	6.5	82
20	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	5.6	81
21	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clinical Immunology and Immunopathology, 1992, 63, 267-274.	2.0	71
22	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nature Reviews Rheumatology, 2014, 10, 35-43.	8.0	70
23	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. British Journal of Haematology, 2004, 126, 85-92.	2.5	68
24	Inflammatory response and the endothelium. Thrombosis Research, 2004, 114, 329-334.	1.7	68
25	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	1.4	67
26	Association of <i>STAT4</i> and <i>BLK</i> , but not <i>BANK1</i> or <i>IRF5</i> , with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2009, 60, 2468-2471.	6.7	66
27	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2002, 61, 608-611.	0.9	65
28	In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus, 1996, 5, 139-145.	1.6	63
29	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus, 2008, 17, 938-943.	1.6	63
30	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
31	Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. Journal of Autoimmunity, 2018, 90, 76-83.	6.5	60
32	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. Journal of Autoimmunity, 2012, 38, J209-J215.	6.5	58
33	Heterogeneity of immune responsiveness in healthy elderly subjects. Clinical Immunology and Immunopathology, 1988, 47, 142-151.	2.0	57
34	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunologic Research, 2013, 56, 432-438.	2.9	57
35	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus, 2010, 19, 453-456.	1.6	53
36	Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Medicine, 2014, 12, 38.	5.5	53

#	Article	IF	CITATIONS
37	β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. Journal of Autoimmunity, 2014, 55, 42-50.	6.5	52
38	Decreased expression of heparinâ€binding epidermal growth factor–like growth factor as a newly identified pathogenic mechanism of antiphospholipidâ€mediated defective placentation. Arthritis and Rheumatism, 2010, 62, 1504-1512.	6.7	51
39	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Frontiers in Immunology, 2018, 9, 1388.	4.8	51
40	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmunity Reviews, 2004, 3, 510-515.	5.8	50
41	Humoral autoimmunity against endothelium: theory or reality?. Trends in Immunology, 2005, 26, 275-281.	6.8	50
42	In vivo immunopotentiating activity of thymopentin in aging humans: Increase of Il-2 production. Clinical Immunology and Immunopathology, 1987, 42, 151-159.	2.0	45
43	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. International Immunology, 2001, 13, 349-357.	4.0	45
44	Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study. Journal of Cellular and Molecular Medicine, 2012, 16, 1563-1572.	3.6	42
45	Obstetric and vascular APS: Same autoantibodies but different diseases?. Lupus, 2012, 21, 708-710.	1.6	41
46	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	1.9	41
47	New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	3.5	40
48	Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. Arthritis Research and Therapy, 2012, 14, R271.	3.5	39
49	Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss. Clinical Reviews in Allergy and Immunology, 2008, 34, 332-337.	6.5	38
50	Update on the pathogenesis and treatment of the antiphospholipid syndrome. Current Opinion in Rheumatology, 2015, 27, 476-482.	4.3	35
51	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus, 2007, 16, 651-656.	1.6	34
52	Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status. Experimental Gerontology, 2014, 54, 14-20.	2.8	34
53	β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. Journal of Immunology, 2017, 198, 2640-2648.	0.8	34
54	Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA. PLoS ONE, 2014, 9, e107743.	2.5	33

#	Article	IF	CITATIONS
55	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Research and Therapy, 2018, 20, 187.	3.5	33
56	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 265.	3.5	33
57	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Research and Therapy, 2016, 18, 111.	3.5	32
58	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. Aids, 1995, 9, 691-694.	2.2	31
59	The challenges of lupus anticoagulants. Expert Review of Hematology, 2016, 9, 389-400.	2.2	31
60	Anti-Beta-2 Glycoprotein I Antibodies Affect Bcl-2 and Bax Trophoblast Expression without Evidence of Apoptosis. Annals of the New York Academy of Sciences, 2006, 1069, 364-376.	3.8	28
61	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. Journal of Autoimmunity, 2009, 32, 60-63.	6.5	28
62	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 773.	4.8	28
63	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/Ipr-Ipr mouse. Immunopharmacology, 1992, 24, 11-16.	2.0	26
64	8-Chloro-Cyclic AMP and Protein Kinase A I-Selective Cyclic AMP Analogs Inhibit Cancer Cell Growth through Different Mechanisms. PLoS ONE, 2011, 6, e20785.	2.5	26
65	Transforming growth factor β1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. Arthritis and Rheumatism, 2006, 54, 356-359.	6.7	25
66	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1764-1769.	2.3	25
67	Role of anti-β2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	6.5	23
68	Toll-like receptor 4 and β ₂ glycoprotein I interaction on endothelial cells. Lupus, 2014, 23, 1302-1304.	1.6	23
69	Synergistic activity of everolimus and 5â€azaâ€2â€2â€deoxycytidine in medullary thyroid carcinoma cell lines. Molecular Oncology, 2017, 11, 1007-1022.	4.6	23
70	Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. Clinical and Experimental Immunology, 2000, 120, 93-100.	2.6	22
71	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1743-1748.	2.3	22
72	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. Autoimmunity Reviews, 2020, 19, 102525.	5.8	22

#	Article	IF	CITATIONS
73	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. Frontiers in Immunology, 2021, 12, 726820.	4.8	21
74	Detection of early endothelial damage in patients with Raynaud's phenomenon. Microvascular Research, 2017, 113, 22-28.	2.5	19
75	Interleukin-17/Interleukin-21 and Interferon-Î ³ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 2019, 104, 2519-2527.	3.5	19
76	The Effects of Deoxyspergualin on the Development of Diabetes in Diabetes-Prone BB Rats. Scandinavian Journal of Immunology, 1992, 36, 415-420.	2.7	18
77	Endothelium activation in the anti-phospholipid syndrome. Biomedicine and Pharmacotherapy, 2003, 57, 282-286.	5.6	18
78	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis and Rheumatism, 2010, 62, 1201-1202.	6.7	17
79	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Annals of the Rheumatic Diseases, 2012, 71, 1388-1392.	0.9	17
80	In vivo immunopotentiating activity of thymopentin in aging humans: Modulation of IL-2 receptor expression. Clinical Immunology and Immunopathology, 1988, 48, 140-149.	2.0	16
81	The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. Endocrine, 2016, 51, 101-112.	2.3	16
82	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. Annals of the Rheumatic Diseases, 2019, 78, e50-e50.	0.9	16
83	Complement Activation and Thrombin Generation by MBL Bound to \hat{I}^22 -Glycoprotein I. Journal of Immunology, 2020, 205, 1385-1392.	0.8	16
84	β-Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. Peptides, 1994, 15, 769-775.	2.4	14
85	International standards for IgG and IgM anti-β2glycoprotein antibody measurement. Lupus, 2014, 23, 1317-1319.	1.6	13
86	Autoantibody profiling in APS. Lupus, 2014, 23, 1262-1264.	1.6	13
87	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews, 2020, 19, 102509.	5.8	13
88	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. Annals of the Rheumatic Diseases, 2021, 80, 1105-1107.	0.9	12
89	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. International Journal of Immunopharmacology, 1991, 13, 1027-1030.	1.1	11
90	Anti-β2-glycoprotein I ELISA assay: The influence of different antigen preparations. Thrombosis and Haemostasis, 2009, 101, 789-791.	3.4	11

#	Article	IF	CITATIONS
91	Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers. Frontiers in Immunology, 0, 13, .	4.8	11
92	Protection from Experimental Autoimmune Thyroiditis in CBA Mice with the Novel Immunosuppressant Deoxyspergualin. Scandinavian Journal of Immunology, 1994, 39, 333-336.	2.7	10
93	Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation. Journal of Endocrinological Investigation, 2017, 40, 761-770.	3.3	10
94	Immunopharmacological activity of cefodizime in young and elderly subjects: In vitro and ex vivo studies. Infection, 1992, 20, S61-S63.	4.7	9
95	Interferon-inducible genes, TNF-related apoptosis-inducing ligand (TRAIL) and interferon inducible protein 27 (IFI27) are negatively regulated in leiomyomas: implications for a role of the interferon pathway in leiomyoma development. Gynecological Endocrinology, 2012, 28, 216-219.	1.7	9
96	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 221-223.	1.9	9
97	Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. International Journal of Molecular Sciences, 2021, 22, 3031.	4.1	9
98	Oxidation of \hat{I}^2 -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. PLoS ONE, 2017, 12, e0186513.	2.5	8
99	β2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2098455.	4.3	8
100	Effects of human recombinant type I IFNs (IFN-α2b and IFN-β1a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: A preliminary study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 192-198.	1.1	7
101	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Analytical Biochemistry, 2019, 566, 133-138.	2.4	7
102	Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients. International Journal of Molecular Sciences, 2021, 22, 5777.	4.1	7
103	Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. RMD Open, 2022, 8, e001902.	3.8	7
104	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. European Journal of Pharmacology, 1996, 311, 213-220.	3.5	5
105	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. Lupus, 2004, 13, 463-468.	1.6	5
106	European Forum on Antiphospholipid Antibodies: research in progress. Lupus, 2009, 18, 924-929.	1.6	5
107	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. Open Rheumatology Journal, 2018, 12, 248-260.	0.2	5
108	Experiences with Immunomodulant Agents in HIV Infections. Acta Haematologica, 1987, 78, 84-90.	1.4	4

#	Article	IF	CITATIONS
109	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. Clinical Immunology and Immunopathology, 1992, 65, 39-44.	2.0	4
110	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES. , 2007, , 725-731.		4
111	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2009, 10, 55-67.	0.1	4
112	Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2–Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays. Immunological Investigations, 2020, 49, 58-68.	2.0	4
113	Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study. Neuroendocrinology, 2020, 111, 937-950.	2.5	4
114	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
115	Antiphospholipid and Antiendothelial Antibodies. International Archives of Allergy and Immunology, 1996, 111, 320-325.	2.1	2
116	8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth. Endocrine, 2017, 56, 388-398.	2.3	2
117	Role of Epigenetic Therapy in the Modulation of Tumor Growth and Migration in Human Castration-Resistant Prostate Cancer Cells with Neuroendocrine Differentiation. Neuroendocrinology, 2022, 112, 580-594.	2.5	2
118	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. International Journal of Immunopharmacology, 1992, 14, 1279-1284.	1.1	1
119	Mechanisms of Action of the Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2017, 12, 31-46.	0.1	1
120	O31â€Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
121	Antibodies and diagnostic tests in antiphosholipid syndrome. , 2021, , 565-574.		1
122	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
123	What is the Genetics of Antiphospholipid Antibodies/Syndrome?. , 2012, , 41-56.		0
124	A5.5â€Antibodies against Domain I of β2 Glycoprotein I in Antiphospholipid Antibody Syndrome. Annals of the Rheumatic Diseases, 2013, 72, A31.3-A32.	0.9	0
125	Antiendothelial Cell Antibodies. , 2014, , 723-729.		0
126	FRI0186â€HYDROXYCHLOROQUINE ON THE TOP OF STANDARD TREATMENT WITH LOW DOSE ASPIRIN AND LOW MOLECULAR WEIGHT HEPARIN SIGNIFICANTLY REDUCES THE PROBABILITY OF PREGNANCY MORBIDITY IN WOMEN WITH MULTIPLE POSITIVITY FOR ANTI-PHOSPHOLIPID ANTIBODIES 2019		0

#	Article	IF	CITATIONS
127	AB0201â€THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		Ο
128	FRI0185â€HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY. , 2019, , .		0
129	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects. , 1990, , 537-550.		0
130	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome. , 2016, , 495-501.		0